Reta 10MG Kit

Description

Retatrutide is a synthetic, lipid-modified 39-amino-acid peptide developed for research into coordinated incretin and glucagon receptor signaling. It is characterized as a tri-agonist with activity at the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). This multi-receptor pharmacology makes retatrutide a scientifically significant tool for examining interconnected pathways involved in energy metabolism, nutrient sensing, glucose regulation, and lipid turnover.

The peptide’s molecular design incorporates sequence modifications that support receptor selectivity and proteolytic stability, along with a fatty-acid-based lipid moiety associated with sustained molecular exposure in experimental pharmacology. Its structure is based on glucagon-related peptide chemistry while incorporating features that enable agonist activity across GLP-1R, GIPR, and GCGR.

In cellular and preclinical research, retatrutide is relevant to studies of cyclic adenosine monophosphate (cAMP)-linked G protein-coupled receptor signaling. Activation of GLP-1R and GIPR is associated with incretin-mediated metabolic signaling, while GCGR activation is relevant to hepatic glucose handling, energy expenditure, and lipid metabolism research. Evaluating the combined activity of these pathways can help researchers investigate receptor crosstalk, signal bias, metabolic adaptation, and the effects of simultaneous agonism at multiple class B GPCRs.

Retatrutide may be used as an analytical reference material or investigational compound in receptor-binding studies, functional signaling assays, peptide stability research, and metabolic disease-model investigations. Its defined peptide architecture and triple-agonist mechanism make it particularly relevant for laboratories studying next-generation incretin biology and multi-target peptide pharmacology.